

Fig. 1A

Malaria antibody group n=5




Fig. 1B

Anti-HBs Antibody Group n=15




Fig. 2A




Fig. 2B




Fig. 3A




Fig. 3B




Fig. 3C-1




Fig. 3C-2




Fig. 4A Animal 907 treated with malaria antibody **Fig. 4B** , Animal 909 treated with anti-HBs antibody




Fig. 4D





Fig. 4C






Fig. 5B Peak viremia 1E11 1E8-1E9 1E9-1E10 1E10-1E11 or late peaked between 1E9-1E10

	970	959	972	968	965	1000	909	996	964
P Values	6.95E-14	2.5E-14	1.04E-14	7.09E-16	4.77E-15	1.03E-13	3.13E-13	1.04E-14	4.24E-9




Fig. 6




Fig. 7

Fig. 8A




Fig. 8B





Figure 9

10/18

ETV

Fig. 10A




Fig. 10B




Fig. 10C




Fig. 10D





Fig. 10E HBV relapse and HBsAg seroclearance



* Only 3 mice received the boosting anti-HBs antibody

Fig. 10F HBV functional cure




Fig. 11A




Fig. 11B




Fig. 11C




Fig. 11D




Fig. 11E





Fig. 11F






Fig. 12A

Fig. 12B




Fig. 12D